JPWO2020154275A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020154275A5
JPWO2020154275A5 JP2021542206A JP2021542206A JPWO2020154275A5 JP WO2020154275 A5 JPWO2020154275 A5 JP WO2020154275A5 JP 2021542206 A JP2021542206 A JP 2021542206A JP 2021542206 A JP2021542206 A JP 2021542206A JP WO2020154275 A5 JPWO2020154275 A5 JP WO2020154275A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
trp
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021542206A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523024A (ja
JP2022523024A5 (https=
JP7672979B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/014382 external-priority patent/WO2020154275A1/en
Publication of JP2022523024A publication Critical patent/JP2022523024A/ja
Publication of JPWO2020154275A5 publication Critical patent/JPWO2020154275A5/ja
Publication of JP2022523024A5 publication Critical patent/JP2022523024A5/ja
Priority to JP2025071352A priority Critical patent/JP2025114614A/ja
Application granted granted Critical
Publication of JP7672979B2 publication Critical patent/JP7672979B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021542206A 2019-01-22 2020-01-21 G12r変異を有するrasに対するhlaクラスii拘束性t細胞受容体 Active JP7672979B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025071352A JP2025114614A (ja) 2019-01-22 2025-04-23 G12r変異を有するrasに対するhlaクラスii拘束性t細胞受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962795203P 2019-01-22 2019-01-22
US62/795,203 2019-01-22
PCT/US2020/014382 WO2020154275A1 (en) 2019-01-22 2020-01-21 Hla class ii-restricted t cell receptors against ras with g12r mutation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025071352A Division JP2025114614A (ja) 2019-01-22 2025-04-23 G12r変異を有するrasに対するhlaクラスii拘束性t細胞受容体

Publications (4)

Publication Number Publication Date
JP2022523024A JP2022523024A (ja) 2022-04-21
JPWO2020154275A5 true JPWO2020154275A5 (https=) 2023-01-31
JP2022523024A5 JP2022523024A5 (https=) 2023-01-31
JP7672979B2 JP7672979B2 (ja) 2025-05-08

Family

ID=69591774

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021542206A Active JP7672979B2 (ja) 2019-01-22 2020-01-21 G12r変異を有するrasに対するhlaクラスii拘束性t細胞受容体
JP2025071352A Pending JP2025114614A (ja) 2019-01-22 2025-04-23 G12r変異を有するrasに対するhlaクラスii拘束性t細胞受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025071352A Pending JP2025114614A (ja) 2019-01-22 2025-04-23 G12r変異を有するrasに対するhlaクラスii拘束性t細胞受容体

Country Status (8)

Country Link
US (2) US12448428B2 (https=)
EP (1) EP3914612A1 (https=)
JP (2) JP7672979B2 (https=)
KR (1) KR102934104B1 (https=)
CN (2) CN113412277B (https=)
AU (1) AU2020211922B2 (https=)
CA (1) CA3127096A1 (https=)
WO (1) WO2020154275A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
WO2025006196A1 (en) 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation
CN119119290B (zh) * 2024-07-15 2025-11-25 上海交通大学医学院附属瑞金医院 靶向flt3 d835h突变衍生新抗原的tcr及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
ES2834070T3 (es) 2011-09-15 2021-06-16 Us Health Receptores de células T que reconocen MAGE restringido por HLA-A1 o HLA-Cw7
WO2015123532A1 (en) * 2014-02-16 2015-08-20 Globeimmune, Inc. Ras g12r immunotherapy for ras mutation-positive cancers
MX384919B (es) * 2014-11-26 2025-03-14 Us Health Receptores de células t de kras anti-mutado.
RU2018101225A (ru) 2015-06-16 2019-07-16 Тарговакс Аса Мутированные фрагменты белка ras
JP7185524B2 (ja) * 2015-09-15 2022-12-07 アメリカ合衆国 Hla-cw8拘束性の変異krasを認識するt細胞受容体
DE102016115246C5 (de) * 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
CN108264550B (zh) * 2017-01-04 2021-04-23 香雪生命科学技术(广东)有限公司 一种识别源自于prame抗原短肽的tcr
CN108395479B (zh) * 2017-02-06 2021-07-16 高军 一种有关kras基因突变的t细胞受体
WO2025006196A1 (en) 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation

Similar Documents

Publication Publication Date Title
JP2021505136A5 (https=)
JP2020534828A5 (https=)
Eiseniohr et al. Expression of a membrane protease enhances presentation of endogenous antigens to MHC class I-restricted T lymphocytes
Fujii et al. A soluble form of the HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4.
RU2752528C2 (ru) Композиции и библиотеки, содержащие рекомбинантные полинуклеотиды, кодирующие Т-клеточные рецепторы, и способы применения рекомбинантных Т-клеточных рецепторов
McMichael et al. Effect of mutations and variations of HLA-A2 on recognition of a virus peptide epitope by cytotoxic T lymphocytes.
GB2609760A (en) HLA Class I-restricted T cell receptors against RAS with G12D mutation
JP2024517884A (ja) p53におけるC135Y、R175H又はM237I変異を認識するT細胞受容体
CN113179631A (zh) 通过临近使能反应疗法开发的共价蛋白质药物
GB2610069A (en) HLA class II-restricted T cell receptors against RAS with G12V mutation
CN113621048A (zh) T细胞抗原受体、其多聚体复合物及其制备方法和应用
WO2023023641A2 (en) Peptide-hla-b*35 libraries, associated compositions, and associated methods of use
CN114302962A (zh) 特异性针对来源于ebv抗原的tcr构建体
JP5189094B2 (ja) 無差別papcd4t細胞エピトープ
CN120607607A (zh) 针对含有g12r突变的ras的hla第ii类限制性t细胞受体
Toshitani et al. Expression of a single-chain HLA class I molecule in a human cell line: presentation of exogenous peptide and processed antigen to cytotoxic T lymphocytes.
JPWO2020154275A5 (https=)
US20230212259A1 (en) Yeast display libraries, associated compositions, and associate methods of use
US8658177B2 (en) Promiscuous HER-2/Neu CD4 T cell epitopes
JPWO2022015694A5 (https=)
CA2386398A1 (en) Modified peptides and peptidomimetics for use in immunotherapy
JPWO2022015922A5 (https=)
JP2023535366A (ja) G12v変異を有するrasに対するhlaクラスii拘束性drb t細胞受容体
GB2614166A (en) T cell receptors recognizing R273C or Y220C mutations in P53
NZ805541A (en) Hla class i-restricted t cell receptors against mutated ras